Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Feb;9(2):157-73.
doi: 10.1586/erv.09.160.

Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists

Matthew Black  1 , Amanda Trent, Matthew Tirrell, Colleen Olive
Affiliations
Review

Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists

Matthew Black et al. Expert Rev Vaccines. 2010 Feb.

Abstract

Considerable success has been made with many peptide antigen formulations, and peptide-based vaccines are emerging as the next generation of prophylactic and remedial immunotherapy. However, finding an optimal platform balancing all of the requirements for an effective, specific and safe immune response remains a major challenge for many infectious and chronic diseases. This review outlines how peptide immunogenicity is influenced by the way in which peptides are presented to the immune system, underscoring the need for multifunctional delivery systems that couple antigen and adjuvant into a single construct. Particular attention is given to the ability of Toll-like receptor agonists to act as adjuvants. A survey of recent approaches to developing peptide antigen delivery systems is given, many of which incorporate Toll-like receptor agonists into the design.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Toll-like receptor signaling pathways
The TLR proteins initiate complex intracellular signaling pathways, resulting in the production of various cytokines that dictate specific immune responses. Typical ligands for the TLR domains are shown. See text for relevant references. AP1: Activator protein 1; IFN: Interferon; IKK: IκBα kinase complex; IRAK: IL-1 receptor-associated kinase; IRF: Interferon regulatory factor; MAL/TIRAP: MyD88 adapter-like TIR domain-containing adapter protein; MAPK: Mitogen-activated protein kinase; MKK: Mitogen-activated protein kinase kinase; MyD88: Myeloid differentiation primary-response gene 88; NAP: NF-κB-activating kinase-associated protein; NEMO: NF-κB essential modulator; ODN: Oligodinucleotide; SAPK/JNK: stress-activated protein kinase/c-Jun NH2-terminal kinase; TAK: Transforming growth factor-β-activated kinase; TBK: TANK-binding kinase; TIR: Toll/IL-1 receptor; TLR: Toll-like receptor; TRAF: TNF receptor-associated factor; TRAM: TRIF-related adapter molecule; TRIF: TIR-domain-containing adapter inducing IFN-β.
Figure 2
Figure 2. Possible peptide antigen delivery systems
Peptide antigen–adjuvant conjugates such as (A) lipid–core peptides; (B) peptide amphiphiles self-assembled into mixed micelles (protein analogous micelles; lipid-based carriers including (C) synthetic, multifunctional vesicles and (D) endogenous exosomes containing peptide-loaded MHC molecules; (E) noninfectious virus-like particles displaying recombinant peptide antigens; (F) microparticles and nanoparticles made from many types of polymers with encapsulated or surface-conjugated peptides; and (G) solid-core nanobeads with conjugated peptides. MPLA: Monophosphoryl lipid A; ODN: Oligodinucleotide; Pam3Cys: Tripalmitoyl-S-glyceryl cysteine; TLR: Toll-like receptor.
See this image and copyright information in PMC

References

    1. Babiuk LA. Broadening the approaches to developing more effective vaccines. Vaccine. 1999;17(13–14):1587–1595. - PubMed
    1. Brown F. Peptide vaccines: fantasy or reality? World J Microbiol Biotechnol. 1992;8(Suppl 1):52–53. - PubMed
    1. Levine MM, Sztein MB. Vaccine development strategies for improving immunization: the role of modern immunology. Nat Immunol. 2004;5(5):460–464. - PubMed
    1. O’Hagan DT, De Gregorio E. The path to a successful vaccine adjuvant – ‘the long and winding road’. Drug Discov Today. 2009;14(11–12):541–551. - PubMed
    1. Purcell AW, Zeng W, Mifsud NA, Ely LK, Macdonald WA, Jackson DC. Dissecting the role of peptides in the immune response: theory, practice and the application to vaccine design. J Pept Sci. 2003;9(5):255–281. Provides a thorough description of how peptides dictate immune responses and follows with ways to design vaccines using defined peptide epitopes. - PubMed

Publication types

MeSH terms

LinkOut - more resources